PDE5 inhibitors in non-urological conditions.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current pharmaceutical design

• Publication date

  2009-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138161209789206980PMID 19860698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats

  2009cited by this paper
• Does sildenafil reverse the adverse effects of ischemia on ischemic colon anastomosis: yes, 'no'.

  2009cited by this paper
• The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction.

  2009cited by this paper
• Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats

  2009cited by this paper
• Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.

  2009cited by this paper
• Phosphodiesterase 5 Inhibition Improves β-Cell Function in Metabolic Syndrome

  2009cited by this paper
• Vision Disorders and Phosphodiesterase Type 5 Inhibitors

  2009cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• The phosphodiesterase‐5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus

  2009cited by this paper
• Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.

  2009cited by this paper
• Hematologic, biochemical, and cardiopulmonary effects of l‐arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy

  2009cited by this paper
• Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress.

  2009cited by this paper
• Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension

  2009cited by this paper
• Cardiovascular effects of phosphodiesterase type 5 inhibitors.

  2009cited by this paper
• Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.

  2009cited by this paper
• Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation

  2009cited by this paper
• Improvement of pulmonary microcirculation after lung transplantation using phosphodiesterase-5 inhibitor modified preservation solution.

  2009cited by this paper
• Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy.

  2009cited by this paper
• Effects of the PDE5-inhibitor vardenafil in a mouse stroke model.

  2009cited by this paper
• Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury.

  2009cited by this paper
• Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?

  2009cited by this paper
• Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model.

  2009cited by this paper
• Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction.

  2009cited by this paper
• Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.

  2009cited by this paper
• Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.

  2009cited by this paper
• Effect of sildenafil on arterial stiffness and wave reflection.

  2009cited by this paper
• Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.

  2009cited by this paper
• Improvement of vascular function by acute and chronic treatment with the PDE‐5 inhibitor sildenafil in experimental diabetes mellitus

  2008cited by this paper
• An Open-Label Pilot Study to Evaluate the Efficacy of Sildenafil Citrate in Middle-Aged Men With Late-Onset Dysthymia

  2008cited by this paper
• Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.

  2008cited by this paper
• Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.

  2008cited by this paper
• PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.

  2008cited by this paper
• Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes

  2008cited by this paper
• The effect of sildenafil on ocular blood flow

  2008cited by this paper
• Endothelium‐mediated Modulation of Ergoreflex and Improvement in Exercise Ventilation by Acute Sildenafil in Heart Failure Patients

  2008cited by this paper
• Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.

  2008cited by this paper
• Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension

  2008cited by this paper
• PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

  2008cited by this paper
• Sildenafil reduces alcohol‐induced gastric damage: just say ‘NO’

  2008cited by this paper
• Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients.

  2008cited by this paper
• Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.

  2008cited by this paper
• Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.

  2008cited by this paper
• Cardiovascular outcomes among sildenafil users: results of the International Men’s Health Study

  2008cited by this paper
• The Effects of Sildenafil Citrate on Ischemic Colonic Anastomotic Healing in Rats: Its Relationship Between Nitric Oxide and Oxidative Stress

  2008cited by this paper
• The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease.

  2008cited by this paper
• Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.

  2008cited by this paper
• Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients

  2008cited by this paper
• Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.

  2008cited by this paper
• Evaluation of the Effect of Sildenafil and Vascular Endothelium Growth Factor Combination Treatment on Skin Flap Survival in Rats

  2008cited by this paper
• Effects of phosphodiesterase‐5 inhibition by sildenafil in the pressure overloaded right heart

  2008cited by this paper
• Magnetic Resonance Imaging Investigation of Axonal Remodeling and Angiogenesis after Embolic Stroke in Sildenafil-Treated Rats

  2008cited by this paper
• Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects

  2008cited by this paper
• Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients.

  2008cited by this paper
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

  2008cited by this paper
• Endothelial effects of drugs designed to treat erectile dysfunction.

  2008cited by this paper
• The Effects of Intraperitoneal Sildenafil Administration on Healing of Left Colonic Anastomoses and Intra-Abdominal Adhesion Formation in the Presence of Intra-Abdominal Infection

  2008cited by this paper
• Sildenafil improves endothelial function in patients with pulmonary hypertension.

  2008cited by this paper
• Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study

  2008cited by this paper
• Phosphodiesterase inhibitors for the treatment of pulmonary hypertension

  2008cited by this paper
• Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance.

  2008cited by this paper
• Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up‐regulation of NO‐cGMP signaling

  2008cited by this paper
• Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.

  2008cited by this paper
• Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension

  2007cited by this paper
• Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

  2007cited by this paper
• Sildenafil Promotes Ischemia-Induced Angiogenesis Through a PKG-Dependent Pathway

  2007cited by this paper
• Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases

  2007cited by this paper
• Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension

  2007cited by this paper
• Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.

  2007cited by this paper
• Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis.

  2007cited by this paper
• Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes.

  2007cited by this paper
• Vardenafil and Weaning from Inhaled Nitric Oxide: Effect on Pulmonary Hypertension in ARDS

  2007cited by this paper
• Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study

  2007cited by this paper
• Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea

  2007cited by this paper
• Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.

  2007cited by this paper
• Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices.

  2007cited by this paper
• Central blood pressure measurements and antihypertensive therapy: a consensus document.

  2007cited by this paper
• Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension

  2007cited by this paper
• Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation

  2007cited by this paper
• Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study.

  2007cited by this paper
• Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient's satisfaction with treatment.

  2007cited by this paper
• Effects of l‐arginine and phosphodiesterase‐5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice

  2007cited by this paper
• Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links.

  2007cited by this paper
• Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea

  2007cited by this paper
• Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.

  2007cited by this paper
• Sildenafil Prevents Cardiovascular Changes after Bone Marrow Fat Embolization in Sheep

  2007cited by this paper
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

  2007cited by this paper
• Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase

  2007cited by this paper
• Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies

  2007cited by this paper
• Long-term use of sildenafil in the therapeutic management of heart failure.

  2007cited by this paper
• Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

  2007cited by this paper
• Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients.

  2007cited by this paper
• Relaxation of the isolated human internal anal sphincter by sildenafil

  2007cited by this paper
• Correctors of Protein Trafficking Defects Identified by a Novel High‐Throughput Screening Assay

  2007cited by this paper
• Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

  2007cited by this paper
• Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow.

  2007cited by this paper
• PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation.

  2007cited by this paper
• Sildenafil extends survival and graft function in a large animal lung transplantation model.

  2006cited by this paper
• Expert consensus document on arterial stiffness: methodological issues and clinical applications.

  2006cited by this paper
• Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

  2006cited by this paper
• PDE5 inhibitors in diabetic peripheral neuropathy

  2006cited by this paper

• Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

  2025cites this paper
• Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis

  2024cites this paper
• Impact of lifestyle on erectile dysfunction: literature review and educational recommendations

  2024cites this paper
• Improvement in Endothelial Function in men taking phosphordiesterase type 5 inhibitors for erectile dysfunction.

  2023cites this paper
• Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs

  2021cites this paper
• The effect of phosphodiesterase-5 inhibitor, tadalafil, on in vitro potassium chloride-induced contractions of isolated human ureteral tissue

  2018cites this paper
• Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction

  2017cites this paper
• Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors

  2017cites this paper
• Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.

  2016cites this paper
• The Prognostic Role of Erectile Dysfunction for Cardiovascular Events

  2015cites this paper
• Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: the beneficial effects of sildenafil.

  2015cites this paper
• Management of Erectile Dysfunction: Therapeutic Algorithm

  2015cites this paper
• PDE-5 inhibitors: clinical points.

  2014cites this paper
• Physical activity on endothelial and erectile dysfunction: a literature review

  2014cites this paper
• Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease

  2014cites this paper
• Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry

  2014cites this paper
• Sildenafil provides sustained neuroprotection in the absence of learning recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats.

  2013cites this paper
• Direct Effects of Vardenafil on the Ureter: In Vitro Investigation and Potential Clinical Applications of Intralumenal Administration

  2013cites this paper
• Managing erectile dysfunction in heart failure.

  2013cites this paper
• Measurement of choroidal perfusion and thickness following systemic sildenafil (Viagra®)

  2013cites this paper
• Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction: A Systematic Review and Meta-Analysis of Cohort Studies

  2012cites this paper
• Beneficial Effect of Vardenafil on Aortic Stiffness and Wave Reflections

  2012cites this paper
• An unheard benefit of phosphodiesterase inhibition

  2012cites this paper
• Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.

  2012cites this paper
• The Role of PDE-5 Inhibitors in Prostate Cancer

  2011cites this paper
• Novel stroke rehabilitation interventions.

  2011cites this paper
• Phosphodiesterases as targets for modulating T-cell responses.

  2011cites this paper
• Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood.

  2011cites this paper
• Macrolides, Azalides, and Ketolides

  2011cites this paper
• Tadalafil pour le traitement de la démence

  2011cites this paper
• Tadalafil zur Behandlung von Demenz

  2011cites this paper
• De winterpenis

  2011cites this paper
• Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.

  2010cites this paper